xRead - Nasal Obstruction (September 2024) Full Articles

20426984, 2021, 3, Downloaded from https://onlinelibrary.wiley.com/doi/10.1002/alr.22741 by Stanford University, Wiley Online Library on [01/07/2024]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License

507

Orlandi et al.

Improvements found in nasal obstruction, hyposmia, rhinorrhea, NP size, and LMscore.

was lower in patients with polyposis. Polypectomy resulted in significant improvements in the

efficacy of macrolides.

reduction in polyp size and IL-8 levels.

Adding long-term low-dose oral macrolides to nasal

steroids was effective in the eradication of biofilm. There is no statistically difference in SNOT-20

scores between 2 groups.

Over half of patients showed clinical improvement.

Peric 1638 2012 3 Cohort study Clarithromycin 500 mg daily (n = 40) NPscore Reduced polyp scores in both non-allergic and allergic patients. Haruna 1639 2009 3 Retrospective Cohort study CTscore Symptom score

Study Year LOE Study Design Study Groups Clinical Endpoint Conclusions CT scan score SNOT-20

The efficacy of macrolides

40% of patients showed

MCP-1 levels in nasal lavage

SEM for biofilm presence

VAS

NPsize

CTscore

NPsize

IL-8 level in nasal lavage IL-4, IL-6, IL-10, and

Symptom score Endoscopy CTscores

2. Clarithromycin 200 mgdaily (n = 23)

furoate nasal spray 200 μ g once daily for 8 weeks (n = 19)

Yamada 1641 2000 3 Cohort study Clarithromycin 400 mg daily for 8 ∼ 12weeks (n = 20)

1. Roxithromycin 150 mg daily (n = 45)

Dabirmoghaddam 1637 2013 3 Cohort study Clarithromycin 500 mg BID for 8 weeks (n = 40)

followed by 250 mg daily for 6 weeks (n = 15)

Korkmaz 1633 2014 2 RCT Clarithromycin 1 gm daily for 2 weeks,

Katsuta 1640 2002 3 Cohort study Roxithromycin 500 mg BID

CRSsNP and CRSwNP:

Mometasone

TABLE X-24 (Continued)